These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 10676597)

  • 21. Clinical criteria for predicting benefit of ICD/PM in post myocardial infarction patients: an AVID and CAST analysis.
    Hallstrom AP; Wyse DG; McAnulty J; ;
    J Interv Card Electrophysiol; 2008 Dec; 23(3):159-66. PubMed ID: 18810620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Do we need a randomized trial of defibrillator therapy in every subset of patients with increased risk of sudden death?
    Exner DV; Klein GJ
    J Cardiovasc Electrophysiol; 2003 Jun; 14(6):574-7. PubMed ID: 12875415
    [No Abstract]   [Full Text] [Related]  

  • 23. What can we expect from prophylactic implantable defibrillators?
    Wilber DJ; Kall JG; Kopp DE
    Am J Cardiol; 1997 Sep; 80(5B):20F-27F. PubMed ID: 9291446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Class III drugs and congestive heart failure: focus on the congestive heart failure-survival trial of antiarrhythmic therapy.
    Singh SN; Fletcher RD
    Am J Cardiol; 1999 Nov; 84(9A):103R-108R. PubMed ID: 10568668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arrhythmic risk stratification of post-myocardial infarction patients.
    Naccarella F; Lepera G; Rolli A
    Curr Opin Cardiol; 2000 Jan; 15(1):1-6. PubMed ID: 10666655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological therapy in coronary heart disease: prevention of life-threatening ventricular tachyarrhythmias and sudden cardiac death.
    Kochs M; Eggeling T; Hombach V
    Eur Heart J; 1993 Sep; 14 Suppl E():107-19. PubMed ID: 8223747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Major clinical trials assessing the prophylactic use of amiodarone in patients with ventricular tachyarrhythmias.
    Fogoros RN
    Control Clin Trials; 1996 Jun; 17(3 Suppl):37S-46S. PubMed ID: 8877266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implantable devices versus antiarrhythmic drug therapy in recurrent ventricular tachycardia and ventricular fibrillation.
    Hohnloser SH
    Am J Cardiol; 1999 Nov; 84(9A):56R-62R. PubMed ID: 10568661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs.
    Yap YG; Camm AJ
    Am J Cardiol; 1999 Nov; 84(9A):83R-89R. PubMed ID: 10568665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of ventricular arrhythmias after recovery from myocardial infarction.
    Mitchell LB
    Annu Rev Med; 1994; 45():119-38. PubMed ID: 7515218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implanted cardioverter-defibrillators are preferable to drugs as primary therapy in sustained ventricular tachyarrhythmias.
    Saksena S; Madan N; Lewis C
    Prog Cardiovasc Dis; 1996; 38(6):445-54. PubMed ID: 8638025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Heart failure].
    Yonezawa M; Komuro I
    Nihon Rinsho; 2002 Jul; 60(7):1422-6. PubMed ID: 12136624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MADIT II, the Multi-center Autonomic Defibrillator Implantation Trial II stopped early for mortality reduction, has ICD therapy earned its evidence-based credentials?
    Coats AJ
    Int J Cardiol; 2002 Jan; 82(1):1-5. PubMed ID: 11786150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.
    Connolly SJ; Gent M; Roberts RS; Dorian P; Roy D; Sheldon RS; Mitchell LB; Green MS; Klein GJ; O'Brien B
    Circulation; 2000 Mar; 101(11):1297-302. PubMed ID: 10725290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone.
    Gali WL; Sarabanda AV; Baggio JM; Ferreira LG; Gomes GG; Marin-Neto JA; Junqueira LF
    Europace; 2014 May; 16(5):674-80. PubMed ID: 24481778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of antiarrhythmic therapy in the management of nonsustained ventricular tachycardia.
    Gomes JA
    Curr Cardiol Rep; 1999 Nov; 1(4):297-301. PubMed ID: 10980857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct clinical features in the recipients of the implantable cardioverter defibrillator in Taiwan: a multicenter registry study.
    Tsai CT; Huang SK; Lin JL; Lai LP;
    Pacing Clin Electrophysiol; 2003 Nov; 26(11):2083-90. PubMed ID: 14622308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol.
    Leite LR; Fenelon G; Simoes A; Silva GG; Friedman PA; de Paola AA
    J Cardiovasc Electrophysiol; 2003 Jun; 14(6):567-73. PubMed ID: 12875414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.